TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Cytologic or histological diagnosis of non-small cell lung cancer~* Patients with disease progression after systemic chemotherapy with two-drug combination regimens that includes a platinum agent or patients with EGFR mutation status who have not been treated~* Patients are diagnosed with multiple brain metastases for the first time in 4 weeks~* Diagnosis of brain metastases is made based on Magnetic resonance imaging (MRI).~* Doctors consider the patient will benefit from WBRT~* No prior brain radiotherapy~* ECOG performance status 0-2~* age:18-75 years~* Neutrophil count ≥1.5×10 to the 9th power/L and platelets≥100×10 to the 9th power/L. hemoglobin ≥90 g/L~* Hepatic: total bilirubin less than or equal to 1.5 times upper limit of normal (ULN) Alanine transaminase (ALT) and aspartate transaminase (AST) less than or equal to 2.5 times ULN (or less than or equal to 5 times ULN in case of known liver involvement)~* Renal: Serum Creatinine less than or equal to 1.5 times upper limit of normal (ULN)~* Patients with measurable brain metastases according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria~* Patients must sign an informed consent indicating that they are aware of the investigational nature of the study~Exclusion Criteria:~* Prior brain radiation therapy~* Solitary brain metastasis according to Magnetic resonance imaging (MRI)~* Mort than 3 extracranial organs have metastatic lesions~* Prior invasive malignancy (skin basal cell cancer, carcinoma in situ of cervix are permissible).~* pregnant or breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Icotinib plus Whole Brain Radiotherapy (Type: EXPERIMENTAL): Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have shown efficacy in advanced non-small cell lung cancer (NSCLC) patients with brain metastases (BM). Icotinib is a new first generation EGFR-TKI. We conducted a phase II study to evaluate the efficacy and safety of icotinib in combination with whole brain radiotherapy （WBRT） in Chinese NSCLC patients with BM and investigated the cerebrospinal fluid (CSF)/ plasma concentrations of icotinib.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women.

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Willing to start or continue oral contraceptive therapy, specifically ethinylestradiol and norethindrone, for the duration of the study~* Consent to a method of birth control in addition to the OC trial medication~* Non-smoking or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months prior to screening~* Body Mass Index (BMI) of 18.0 to 30.0 kg/m2, extremes included~* Healthy on the basis of a physical examination, medical history, electrocardiogram, vital signs and the results of blood biochemistry and hematology tests and a urinalysis carried out at screening.~Exclusion Criteria:~* The most important eligibility criteria are: Not pregnant or breastfeeding~* Not postmenopausal~* No positive HIV test~* No alcohol or barbiturate, amphetamine, recreational or narcotic drug use~* No hepatitis A, B or C infection~* No currently active gastrointestinal, cardiovascular, neurologic, psychiatric, metabolic, renal, hepatic, respiratory, inflammatory or infectious disease~* No history of significant skin disease~* No previously demonstrated clinically significant allergy or hypersensitivity to any of the excipients of the medication administered in this trial (i.e. TMC278, Ovysmen®)~* No clinical significant abnormal finding in the gynaecological examination~* No currently active gynaecological disorders~* No major medical condition that would preclude the safe administration of oral contraceptive therapy~* No participation in an investigational drug trial within 60 days prior to the start of the first OC cycle

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~* male or female patients with either breast or head and neck cancer~* diagnosis of mild to moderate uncomplicated lymphoedema~* age 18 or over~* under the care of the lymphoedema service for at leas:~* two months (head and neck cancer patients)~* three months (breast cancer patients)~* no active cancer disease~* at least 3 months since prior active cancer treatment (surgery, radiotherapy, chemotherapy, intravenous treatment)~* more than 6 months since prior acupuncture treatment~* concurrent adjuvant hormonal therapy allowed~* concurrent anti-depressant medication allowed provided there has been no change in prescription or dosing within the past 3 months and patient intends to remain on the medication for the duration of study treatment and follow-up~* Able to understand and communicate in English~* Able to travel to the Lynda Jackson Macmillan Centre for treatment~* Able to attend treatment once weekly for at least 7 consecutive weeks~* Able to complete outcome measures~EXCLUSION CRITERIA:~* bilateral breast cancer~* advanced cancer disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual treatment plus acupuncture (Type: EXPERIMENTAL): Acupuncture and moxibustion, individualised according to participant priorities, delivered once weekly for 7 treatments (Series 1) followed by 6 treatments (Series 2) if participant wishes to continue treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lidocaine Combined Dexmedetomidine for Obturator Nerve Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects scheduled to undergo elective operation of TURBT on lateral wall for whom ONB was needed diagnosed through cystoscopy or CT examination preoperatively.~2. Subject's American Society of Anesthesiologists physical status is I-II.~3. The subject's parent/legally authorized guardian has given written informed consent to participate.~Exclusion Criteria:~1. Subject has a diagnosis of abnormal coagulation function.~2. Subject has a diagnosis of Diabetes mellitus.~3. Subject has a preexisting neurologic deficits of the lower extremities.~4. Subject has a history of alcohol or drug abuse.~5. Subject is pregnant or breast-feeding.~6. Subject is obese (body mass index \>30kg/m2).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Dexmedetomidine (Type: ACTIVE_COMPARATOR): Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
- Normal Saline (Type: PLACEBO_COMPARATOR): Normal Saline is administrated as an adjuvant of lidocaine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Study the Influence of Growth Factors on Bone Marrow and Hepatic Regeneration in Patients With Decompensated Cirrhosis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18-65 years~* All patients who are known to have cirrhosis of liver with portal hypertension and are compensated on presentation with no features of ascites/ jaundice/ bleed/ HE/ HRS.~* Only patients with alcoholic cirrhosis and cryptogenic cirrhosis (etiology work up negative) will be enrolled in the study.~Exclusion Criteria:~* Sepsis ( Any culture positive: blood, urine, any other obvious source of infection: UTI, LRTI)~* Variceal bleed in the past 3 months~* Autoimmune disorders~* HCC (Hepatocellular Carcinoma)~* Multi organ failure~* Any features of decompensation in form of ascites/Jaundice/ HE (grade 3 or 4) / HRS~* HIV seropositivity~* Essential hypertension~* Pregnancy~* Refusal to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- G-CSF + Erythropoietin (Type: EXPERIMENTAL): None
- G-CSF (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Network Support for Alcohol Treatment 2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 yo~* meets Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for alcohol dependence~Exclusion Criteria:~* acute medical or psychiatric problems that require inpatient treatment (e.g., acute psychosis, or suicide/homicide risk)~* reading ability below the fifth grade level~* lack of reliable transportation to the treatment site, or excessive commuting distance~* inability to understand English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Network Support (Type: EXPERIMENTAL): Network Support treatment is aimed at helping patients change their social support network so that it supports abstinence. In this treatment patients will be encouraged to attend AA meetings and engage in other activities that would involve non-drinkers. These activities would be determined by the patient, with help from the therapist. Patients would learn about methods of avoiding drinking, making new friends, and getting enjoyment from activities other than drinking. In addition patients will learn specific skills intended to help them make new acquaintances and change their circle of friends.
- Packaged Cognitive-Behavioral Treatment (Type: ACTIVE_COMPARATOR): The purpose of Packaged Cognitive-Behavioral Treatment (PCBT) is to train patients in a variety of skills that they can use to keep themselves from drinking.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iron-fortified Whole Maize Flour Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:Children:~* 3-8 years age (for the purposes of this study this will include children born within the period December 15th 1995- May 1st 2001).~* Whohave been resident in the area for 6 months or more.~* Enrolled in the selected schools~* Able to consume the target amount of porridge, at least 50% of the time during the run-in period~* Will be present in the study area for the entire study period (April - December 2004).~Exclusion Criteria:~* Children below 3 years and above 8 years of age (born after December 15th 1995 and before May 1st 2001).~* Children who have been resident in the area for less than 6 months at the time of recruitment.~* Children with obvious physical and mental disability.~* Severely malnourished children.~* Severely anaemic children (Hb \<70g/L).

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 8 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic, well-compensated stable liver~* Hypercholesterolemia~Exclusion Criteria:~* Signs or symptoms of ascites, jaundice, or cirrhosis with a Child-Pugh Score \> 5~* History of disorders affecting serum bilirubin levels, more than 1 chronic liver disease, significant endocrine, renal, or gastrointestinal disease, or uncontrolled hypertension~* Treatment with lipid-lowering drugs, unless they have been withdrawn within the timeframe specified in the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S9912 Combination Chemo in Stage III Ovarian Cancer,

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage III ovarian epithelial, fallopian tube, or primary peritoneal carcinoma~  * Tumor involves one or both ovaries with microscopically confirmed peritoneal metastasis outside the pelvis and/or regional lymph node metastasis~ * No tumors of borderline or low malignant potential only~ * Mixed Mullerian tumors allowed~* Must have optimal disease defined as no residual lesions after resection or residual disease such that no single lesion measures greater than 1 cm in diameter~* Must have undergone staging exploratory laparotomy with tumor debulking within the past 70 days~PATIENT CHARACTERISTICS:~Age:~* Not specified~Performance status:~* SWOG 0-1~Life expectancy:~* Not specified~Hematopoietic:~* Granulocyte count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic:~* Bilirubin ≤ 2 times upper limit of normal (ULN)~* SGOT or SGPT ≤ 2 times ULN~Renal:~* Creatinine clearance ≥ 50 mL/min~Cardiovascular:~* No congestive heart failure~* No cardiac arrhythmia~* No myocardial infarction or unstable angina within the past 6 months~* Patients with a history of myocardial disease must not have ischemia or pathologic arrhythmias and must have an ejection fraction \> 50% by MUGA~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception~* No active or uncontrolled infection~* No concurrent fever~* No grade 2 or greater sensory neuropathy~* No severe gastrointestinal symptoms (i.e., partial obstruction) and/or bleeding, diarrhea, or abdominal tenderness suggestive of peritoneal irritation or infection~* No erythema or tenderness of abdominal incision or port site suggestive of underlying infection~* No other malignancy within the past five years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior immunotherapy for ovarian cancer~Chemotherapy:~* No prior chemotherapy for ovarian cancer~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior pelvic radiotherapy for ovarian cancer~Surgery:~* See Disease Characteristics~* Recovered from all reversible surgery-related toxic effects~Other:~* No other concurrent antitumor treatment~* No concurrent antibiotics for infection of undetermined etiology

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel/cisplatin/Liposomal Doxorubicin (Type: EXPERIMENTAL): paclitaxel, cisplatin and liposomal doxorubicin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* adults or children weighing ≥ 10 kg~* residing in the zone covered by the investigating centre throughout the entire follow-up period~* capable of receiving oral treatment~* axillary temperature ≥ 37.5 degrees Celsius at the inclusion visit or history of fever within the previous 24 hours~* infection with Plasmodium falciparum, with parasite density in the blood ranging from 1000 to 200,000 asexual forms per cubic millimetre~* informed consent from each participant or parents (guardians) for the children~* negative urinary pregnancy test for all women of child-bearing age~Exclusion criteria:~* presence of at least one serious or clinical danger sign of malaria: prostration, consciousness disorders, recent and repeated convulsions , respiratory distress, inability to drink, uncontrollable vomiting, macroscopic haemoglobinuria, jaundice, haemorrhagic shock, systolic Blood Pressure \< 70 mmHg in adults or \< 50 mmHg in children, spontaneous bleeding, inability to sit or stand~* serious concomitant disease~* allergy to one of the investigational medicinal products (drug substance or excipient)~* pregnant women (reported, clinically visible or palpable pregnancy, or positive urinary pregnancy test), or breast-feeding women~* clinically documented heart disease (bradycardia, extrasystoles, exertional dyspnoea, systolic or diastolic extrasystoles, gallop rhythm...)~* history of hepatic and (or) haematological impairment during treatment with amodiaquine~* intake of medication metabolised by cytochrome CYP2D6 (e.g. metoprolol, flecainide, imipramine, amitriptyline, clomipramine) or CYP3A4 (e.g. erythromycin, ketoconazole, itraconazole, cimetidine, HIV protease inhibitors)~* family history of congenital QTc prolongation or sudden death or another clinical condition known to prolong the QTc interval~* intake of medication known to prolong the QTc interval, such as class IA and III antiarrythmics, neuroleptics, antidepressant agents, certain antibiotics including drugs in the macrolide class, fluoroquinolones, imidazole and triazole, antifungal agents, certain non-sedative antihistamines (terfenadine, astemizole) and cisapride~* certain known electrolyte imbalances such as hypokalaemia or hypomagnesaemia~* patient having received artesunate + amodiaquine or artemether + lumefantrine at a suitable dosage within 30 days prior to inclusion~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Propolis Effects in Patients With Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* older than 18 years;~* less than 90 years;~* glomerular filtration rate between 25 and 70 ml / min;~* proteinuria in the urine 24 hours more than 300 mg or protein / creatinina in isolated urine greater than 0.3g / g or microalbuminuria (albumin / creatinine ratio) between 30-300 mg / g.~Exclusion Criteria:~* Pregnants;~* Neoplasia carrier;~* Renal transplant patients;~* Patients who refuse to participate in the study.~* Glomerulopathy on Immunosuppression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Propolis (Type: ACTIVE_COMPARATOR): Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses.
- Placebo (Type: PLACEBO_COMPARATOR): Patients will continue to receive standard treatment for their comorbidities, determined by the attending physician. Patients will receive 500 mg / day of the propolis-placebo in the form of tablets split in two daily doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Methylphenidate in Myotonic Dystrophy Type 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adults~* Epworth score ≥ 10~* Diagnosis of myotonic dystrophy type 1~Exclusion Criteria:~* hypersensibility to methylphenidate~* Pregnancy~* Patients who receive drugs that interfere with methylphenidate~* Cognitive impairment~* Sleep apnea

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Methylphenidate versus baseline (Type: PLACEBO_COMPARATOR): None
- Arm 2: Placebo versus baseline (Type: PLACEBO_COMPARATOR): One table placebo per day during 3 week

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete